• Pressemitteilung BoxID 499835

Genentech and Pfizer Share CDx Success Insights at the 4th Molecular Diagnostics for Cancer Drug Development in Boston

(PresseBox) (London, UK, ) The final agenda has been released for the 4th Molecular Diagnostics for Cancer Drug Development meeting (Boston, June 25th - 28th 2012).

The 3 day agenda features 31 expert speakers including the key project leaders of Zelboraf (Genentech) and Xalkori (Pfizer) on overcoming the scientific and commercial hurdles of targeting a drug to a specific patient subpopulation, and how they gained regulatory approval of their companion diagnostics last year.

They join oncology and diagnostics experts representing: Clovis Oncology, MD Anderson Cancer Center, Johnson & Johnson, National Cancer Institute, Astellas Pharma, Fred Hutchinson Cancer Research Center, The Biomarkers Consortium, Novartis, Daiichi-Sankyo, FDA, ImmunoGen, Bristol-Myers Squibb, Morphotek, Eisai, Bayer, Dana-Farber Cancer Institute, AVEO Pharmaceuticals, Celgene and Merck.

Visit the event website or download the brochure to see the full speaker line up and agenda.

Diese Pressemitteilungen könnten Sie auch interessieren

Vascular Intervention: BIOSOLVE-II Trial Establishes Safety and Clinical Performance of World's First Clinically Proven Magnesium Bioresorbable Scaffold

, Medizintechnik, BIOTRONIK

BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, has announced results from the BIOSOLVE-II trial investigating...

Therapieliege für Schwergewichte

, Medizintechnik, Schupp GmbH & Co KG

Eine Therapieliege für schwerere Patienten hat die Schupp GmbH & Co. KG seit kurzem im Programm. Die Therapieliege ATLAS ist bis 250 Kilogramm...

exceet Manufactures Innovative Post-Urography System

, Medizintechnik, exceet Group AG

Sense-of-balance analysis supports diagnosis and therapy for neurology, orthopedics, sports medicine exceet as a partner for development, prototyping,...